COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease

The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the causative factor behind the 2019 global coronavirus pandemic (COVID-19). The main protease, known as M(pro), is encoded by the viral genome and is essential for viral replication. It has also been an effective target for drug de...

Descripción completa

Detalles Bibliográficos
Autores principales: Kronenberger, Thales, Laufer, Stefan A., Pillaiyar, Thanigaimalai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Keynote
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074736/
https://www.ncbi.nlm.nih.gov/pubmed/37028502
http://dx.doi.org/10.1016/j.drudis.2023.103579
Descripción
Sumario:The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the causative factor behind the 2019 global coronavirus pandemic (COVID-19). The main protease, known as M(pro), is encoded by the viral genome and is essential for viral replication. It has also been an effective target for drug development. In this review, we discuss the rationale for inhibitors that specifically target SARS-CoV-2 M(pro). Small molecules and peptidomimetic inhibitors are two types of inhibitor with various modes of action and we focus here on novel inhibitors that were only discovered during the COVID-19 pandemic highlighting their binding modes and structures.

Ejemplares similares